As albumin-bound paclitaxel nanoparticles (Abraxane) have been approved by the FDA for the treatment of metastatic breast cancer and non-small cell lung cancer (NSCLC)41, 42, and the limited supply of the first FDA-approved nano-drug Doxil in recent years43, the results from our current study signifies that CD44-targeted HA-PEI/HA-PEG nanoparticle platform can be an effective delivery system for siRNA-based anticancer therapeutics in treating drug resistant ovarian cancer. The gene discussed is CD44; the disease is non-small cell lung carcinoma.